This series reviews public health challenges and prevention strategies for chronic liver diseases in Europe, indicating a need for action.
In their latest Series, The Lancet Regional Health – Europe provides a comprehensive overview of the public health challenges, policy readiness, diagnostic innovations, and care models related to metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and viral hepatitis in Europe.1–4 Noting the public health burden of these preventable, chronic liver diseases, we find it timely to highlight the risk factors for MASLD and opportunities for prevention.
No takes yet. Share an insight, caveat, or question.
García-Larsen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: